Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled “Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials,” which published online November 11, 2019, and in print in February 2020 in JAMA Neurology,1 there was an error in the Biomarkers subsection of the Results section. The mean data for lanabecestat 20 mg vs placebo in DAYBREAK-ALZ was 2.2 Centiloids not −2.2 Centiloids. This article was corrected online.
Error in the Biomarker Subsection. JAMA Neurol. 2020;77(9):1179. doi:10.1001/jamaneurol.2020.2416
Create a personal account or sign in to: